NCT07314723

9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer

A Single Arm, Open-label, Multicenter, Phase II Clinical Study to Evaluate the Safety and Efficacy of 9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 90 (estimated)
• Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a single arm, open-label, multicenter phase II clinical study to evaluate the safety and efficacy of 9MW2821 combined with Toripalimab in perioperative patients with urothelial cancer.

Conditions

• Urothelial Carcinoma

Interventions

Type	Name	Description
DRUG	9MW2821	9MW2821, 1.25mg/kg, intravenous (IV) infusion
DRUG	Toripalimab Injection	Toripalimab, 240mg, intravenous (IV) infusion

Timeline

• Start date: 2025-08-01
• Primary completion: 2027-12-31
• Completion: 2028-12-31
• First posted: 2026-01-02
• Last updated: 2026-01-02

Locations

1 site across 1 country: China